文献速递免疫规划传染病防控与疫情报告

辉瑞和莫德纳新冠疫苗在医护人员中的中期有效性估计

Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2021-05-21

本研究为在美国33个站点开展的检测阴性病例对照研究,评估mRNA新冠疫苗对有症状感染的有效性。中期分析显示,单剂疫苗调整后有效性为82%(95%CI 74%-87%),两剂为94%(95%CI 87%-97%),与临床试验结果一致,支持两剂疫苗对成人有症状疾病的强保护作用。

要点

  • 单剂mRNA疫苗对有症状感染的有效性为82%(95%CI 74%-87%)。
  • 两剂疫苗有效性达94%(95%CI 87%-97%),保护作用更强。
  • 该真实世界数据支持mRNA疫苗在医护人员中的使用。

核心结论

  • mRNA新冠疫苗在医护人员中显示出与临床试验相当的有效性,两剂接种提供强保护。

研究设计与样本

  • 检测阴性病例对照研究,在美国25个州的33个站点医护人员中开展,评估mRNA疫苗对有症状疾病的有效性。

主要发现

  • 单剂疫苗(首剂后14天至第二剂后6天)调整后有效性为82%(95%CI 74%-87%)。
  • 两剂疫苗(第二剂后≥7天)调整后有效性为94%(95%CI 87%-97%)。
  • 调整因素包括年龄、种族/民族和基础疾病。

临床怎么用

  • 支持医护人员接种两剂mRNA新冠疫苗以预防有症状感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Throughout the COVID-19 pandemic, health care personnel (HCP) have been at high risk for exposure to SARS-CoV-2, the virus that causes COVID-19, through patient interactions and community exposure (1). The Advisory Committee on Immunization Practices recommended prioritization of HCP for COVID-19 vaccination to maintain provision of critical services and reduce spread of infection in health care settings (2). Early distribution of two mRNA COVID-19 vaccines (Pfizer-BioNTech and Moderna) to HCP allowed assessment of the effectiveness of these vaccines in a real-world setting. A test-negative case-control study is underway to evaluate mRNA COVID-19 vaccine effectiveness (VE) against symptomatic illness among HCP at 33 U.S. sites across 25 U.S. states. Interim analyses indicated that the VE of a single dose (measured 14 days after the first dose through 6 days after the second dose) was 82% (95% confidence interval [CI] = 74%-87%), adjusted for age, race/ethnicity, and underlying medical conditions. The adjusted VE of 2 doses (measured ≥7 days after the second dose) was 94% (95% CI = 87%-97%). VE of partial (1-dose) and complete (2-dose) vaccination in this population is comparable to that reported from clinical trials and recent observational studies, supporting the effectiveness of mRNA COVID-19 vaccines against symptomatic disease in adults, with strong 2-dose protection.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Pilishvili T, Fleming-Dutra KE, Farrar JL, et al. Interim Estimates of Vaccine Effectiveness of Pfizer-BioNTech and Moderna COVID-19 Vaccines Among Health Care Personnel - 33 U.S. Sites, January-March 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34014909. doi:10.15585/mmwr.mm7020e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。